AU2003248052A1 - N-phenyl-(2r,5s)dimethylpiperadine derivative - Google Patents

N-phenyl-(2r,5s)dimethylpiperadine derivative

Info

Publication number
AU2003248052A1
AU2003248052A1 AU2003248052A AU2003248052A AU2003248052A1 AU 2003248052 A1 AU2003248052 A1 AU 2003248052A1 AU 2003248052 A AU2003248052 A AU 2003248052A AU 2003248052 A AU2003248052 A AU 2003248052A AU 2003248052 A1 AU2003248052 A1 AU 2003248052A1
Authority
AU
Australia
Prior art keywords
dimethylpiperadine
phenyl
derivative
dimethylpiperadine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248052A
Other languages
English (en)
Inventor
Takashi Furutani
Masahiko Hayakawa
Masakazu Imamura
Hiroyuki Kaizawa
Kenichi Kawaguchi
Takenori Kimura
Isao Kinoyama
Minoru Okada
Nobuaki Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU2003248052A1 publication Critical patent/AU2003248052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003248052A 2002-07-12 2003-07-11 N-phenyl-(2r,5s)dimethylpiperadine derivative Abandoned AU2003248052A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-203690 2002-07-12
JP2002203690 2002-07-12
PCT/JP2003/008860 WO2004007471A1 (ja) 2002-07-12 2003-07-11 Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体

Publications (1)

Publication Number Publication Date
AU2003248052A1 true AU2003248052A1 (en) 2004-02-02

Family

ID=30112682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248052A Abandoned AU2003248052A1 (en) 2002-07-12 2003-07-11 N-phenyl-(2r,5s)dimethylpiperadine derivative

Country Status (11)

Country Link
US (2) US7297698B2 (enExample)
EP (1) EP1557411B1 (enExample)
JP (1) JP4449746B2 (enExample)
AU (1) AU2003248052A1 (enExample)
CA (1) CA2492138C (enExample)
CY (1) CY1113335T1 (enExample)
DK (1) DK1557411T3 (enExample)
ES (1) ES2393333T3 (enExample)
PT (1) PT1557411E (enExample)
SI (1) SI1557411T1 (enExample)
WO (1) WO2004007471A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
WO2005108399A1 (ja) * 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
MX2009000508A (es) * 2006-07-14 2009-01-27 Pfizer Prod Inc Sal tartrato de (7s)-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-me tilpiperazin-1-il]-6,7-dihidro-5h-ciclopenta[b]piridina.
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CN102548991B (zh) 2009-09-24 2015-03-25 霍夫曼-拉罗奇有限公司 作为磷酸二酯酶10a抑制剂的咪唑并吡啶或咪唑并嘧啶衍生物
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
EP2539706B1 (en) * 2010-02-24 2015-03-04 Research Triangle Institute Arylpiperazine opioid receptor antagonists
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
TW201305130A (zh) * 2010-10-22 2013-02-01 Astellas Pharma Inc 突變雄激素受體拮抗藥
WO2013058361A1 (ja) 2011-10-21 2013-04-25 アステラス製薬株式会社 アンドロゲン受容体拮抗化合物の結晶
US8765767B2 (en) * 2012-03-16 2014-07-01 Bristol-Myers Squibb Company Positive allosteric modulators of mGluR2
PL3231800T3 (pl) * 2014-12-08 2020-04-30 Lsk Nrdo Co., Ltd. Nowa pochodna 4-(arylo) -n-(2-alkoksytieno[3,2-b]pirazyn-3-ylo)-piperazyno-1-karboksyamidu oraz jej działanie antyproliferacyjne
WO2016196955A1 (en) 2015-06-04 2016-12-08 Drexel University Inhibitors of RAD52 Recombination Protein and Methods Using Same
CN105130847A (zh) * 2015-09-10 2015-12-09 成都大学 一种制备高纯邻甲基苯腈及其衍生物的方法
SG11201811225RA (en) 2016-06-22 2019-01-30 Radius Health Inc Ar+ breast cancer treatment methods
SG11202009388XA (en) 2018-03-26 2020-10-29 Basf Se Novel hyperbranched polyesters and their use as wax inhibitor, as pour point depressant, as lubricant or in lubricating oils
EP4034114A4 (en) * 2019-09-23 2023-07-26 Accutar Biotechnology Inc. NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES
AU2022333206A1 (en) 2021-08-27 2024-04-11 Basf Se Aqueous dispersions of paraffin inhibitors
AU2022336800A1 (en) 2021-08-30 2024-04-11 Basf Se Hyperbranched polyesters modified with branched fatty acids and their use as paraffin inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4694004A (en) * 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
BR9914018A (pt) * 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
JP2001328938A (ja) * 2000-03-17 2001-11-27 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体を有効成分とする医薬
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives

Also Published As

Publication number Publication date
JP4449746B2 (ja) 2010-04-14
US20050261303A1 (en) 2005-11-24
US7666873B2 (en) 2010-02-23
CA2492138C (en) 2011-01-11
WO2004007471A1 (ja) 2004-01-22
ES2393333T3 (es) 2012-12-20
JPWO2004007471A1 (ja) 2005-11-17
US7297698B2 (en) 2007-11-20
EP1557411A1 (en) 2005-07-27
EP1557411B1 (en) 2012-10-17
CA2492138A1 (en) 2004-01-22
CY1113335T1 (el) 2016-06-22
EP1557411A4 (en) 2011-02-23
SI1557411T1 (enExample) 2013-01-31
DK1557411T3 (da) 2012-11-05
US20080214543A1 (en) 2008-09-04
PT1557411E (pt) 2012-11-22

Similar Documents

Publication Publication Date Title
AU2003248052A1 (en) N-phenyl-(2r,5s)dimethylpiperadine derivative
AU2002950670A0 (en) Easy clamp
AU2003303088A1 (en) Light-emitting arrangement
AU2003281694A1 (en) 6,11-4-carbon bridged ketolides
AU2003294726A1 (en) Window-winding arrangement
AU2003236962A1 (en) Wear-indicating filament
AU2003285320A1 (en) Vaccine
AU2003261801A1 (en) Novel depsipeptide compound
AU2003208464A1 (en) Improved pointing device
AU2003900339A0 (en) Planting arrangement
AU2002950473A0 (en) Expression system
AU2003299169A1 (en) Flash emulator
AU2003246971A1 (en) Tranquilliser dart
AU2003243065A1 (en) Grin-lens arrangement
AU2003205800A1 (en) Forest machine
AU2003254555A1 (en) S. aureus antigene
AU2003230738A1 (en) Active-loop, spatially-combined amplifier
AU2003224130A1 (en) Benzoxazinone derivative
AU2003240117A1 (en) Hoses
AU2003263548A1 (en) Vliw processor with variable, address range dependent issue-width
AU2002358825A1 (en) Improved scissors
AU2003268985A1 (en) Cannula
AU2002312270A1 (en) Carrousel file
AU2002334492A1 (en) Chair with support, specifically for shooting
AU2003244272A1 (en) Segment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase